- Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivoTroy A Luster
Department of Oncology Research, Human Genome Sciences, Inc, Rockville, Maryland, United States of America
PLoS ONE 7:e47361. 2012..Together, these findings suggest BLyS has significant potential as a targeting ligand for the delivery of cytotoxic "payloads" to malignant B cells...
- Trail receptors: targets for cancer therapyRobin C Humphreys
Human Genome Sciences, Oncology Research Department, Rockville, MD 20850, USA
Adv Exp Med Biol 615:127-58. 2008..Receptor agonist molecules including forms of the native ligand and monoclonal antibodies are being developed and tested as therapeutics in the treatment of human cancer...